Latest Pluripotency Stories
Better understanding of mechanisms involved should improve reprogramming of embryonic-like cells.
Officials at the Vatican announced on Friday they will begin financing research into the medical use of adult stem cells.
MADISON, Wis., April 21 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A.
Finding is expected to steer future work on therapies down the most efficient and promising paths.
A new technique for reprogramming human adult cells could greatly improve the safety and efficiency of producing patient-specific stem cells for use in a range of therapeutic applications to repair or replace damaged or diseased tissues.
At Rutgersâ€™ Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem cells and their potential use in treating diseases, repairing damaged organs, and drug development.
The groundbreaking new findings will speed research on potential therapies.
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body.
MADISON, Wis., March 2 /PRNewswire/ -- Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.
SAN DIEGO, Feb. 26 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world.